{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:12:53Z","timestamp":1774991573975,"version":"3.50.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7232118"],"award-info":[{"award-number":["7232118"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-092"],"award-info":[{"award-number":["2022-PUMCH-B-092"]}]},{"name":"the National Key Clinical Specialty Project of China"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:p>Telitacicept, a TACI-Fc fusion that neutralizes BAFF\/APRIL, was administered weekly (160\u2005mg) to two women with pemphigus foliaceus who declined systemic corticosteroids and conventional immunosuppressants. Rapid disease control ensued (Pemphigus Disease Area Index score of 0 by weeks 8\u201310) with normalized anti-Dsg1 titres and sustained remission over 6\u2005months; treatment was well tolerated without interruption. These preliminary observations, which represent, to our knowledge, the first use of telitacicept in pemphigus foliaceus, support BAFF\/APRIL blockade as a potential steroid-sparing strategy.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf535","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:31:59Z","timestamp":1766752319000},"page":"804-806","source":"Crossref","is-referenced-by-count":1,"title":["B-cell-activating factor and A proliferation-inducing ligand (BAFF\/APRIL) blockade with telitacicept in pemphigus foliaceus: two cases"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4947-2899","authenticated-orcid":false,"given":"Si-Hang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3646-3505","authenticated-orcid":false,"given":"Si-Han","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7857-0906","authenticated-orcid":false,"given":"Si-Zhe","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-4331","authenticated-orcid":false,"given":"Ya-Gang","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"2026031913323719800_ljaf535-B1","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2026031913323719800_ljaf535-B2","doi-asserted-by":"crossref","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026031913323719800_ljaf535-B3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026031913323719800_ljaf535-B4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/bjd\/ljaf023","article-title":"Exploring telitacicept in a patient with pemphigus vulgaris","volume":"192","author":"Zhang","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026031913323719800_ljaf535-B5","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1002\/mco2.515","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"(2020) 2024","journal-title":"MedComm"},{"key":"2026031913323719800_ljaf535-B6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf535\/66148826\/ljaf535.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/804\/66148826\/ljaf535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/804\/66148826\/ljaf535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:32:46Z","timestamp":1773941566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/4\/804\/8407014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":6,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf535","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,29]]}}}